This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu
Trial record 1 of 13 for:    autoimmune disease | long covid
Previous Study | Return to List | Next Study

Investigating Development of Autoimmunity in Post-Acute COVID-19 Syndrome (PACS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05459506
Recruitment Status : Recruiting
First Posted : July 15, 2022
Last Update Posted : February 14, 2023
Information provided by (Responsible Party):
McMaster University

Brief Summary:
The coronavirus pandemic has severely affected healthcare systems and changed life as everyone know it, globally. Apart from the acute phase disease complications, it is now apparent that a significant proportion (15%) of patients who recover continue experiencing symptoms such as chronic fatigue, shortness of breath, joint pains, cognitive impairment ("brain fog"), etc. for several months, if not for life. This syndrome has been labeled as "long-COVID" or Post-Acute COVID-19 Syndrome (PACS) and can happen to anyone whether you're young, old, healthy, or have a chronic illness. One can get it even if the COVID-19 symptoms were mild. There is no confirmed cause as to why this happens. However, there is data to support that inappropriate activation of the immune system by the virus may play a role. While our immune system is programmed to protect us against foreign invaders (such as viruses), in this case, it is directed against elements of our own. The net result is autoimmunity, where the immune system produces autoantibodies that cause damage to the body. This may lead to the development of chronic and serious diseases like lupus, rheumatoid arthritis, vasculitis, scleroderma, and others.The aim of our study is to understand the exact impairment of the immune system, why these patients develop autoantibodies, characterize their impact on the clinical symptoms of PACS, and, potentially, identify ways to modify this. The study's impact is significant since it is projected that 150000 Canadians will experience (or are already experiencing) this syndrome.

Condition or disease
COVID-19 Pandemic

Detailed Description:

Background: As of April 10th, 2021, >1 million Canadians have contracted Coronavirus-2019-disease (COVID-19), with 398,835 infected in Ontario of whom 92% are deemed "recovered" by public health. Despite the recovery, a considerable section (10-15%) of COVID-19 survivors, irrespective of their severity (hospitalized or mild), continue to have symptoms or develop new ones. These vary in type and severity between individuals, ranging chronic fatigue, anosmia, dyspnea, diffuse pain, anxiety, cognitive impairment that is not attributed to any clinical diagnosis. This is now termed the Post-Acute COVID-19 Syndrome (PACS) or long-COVID. Much remains unknown as to what underlies this constellation of symptoms and what more severe pathologies it can lead to.

Rationale to study autoimmunity in PACS: First, diverse circulating auto antibodies and lymphopenia are associated with COVID-19 severity. Second, though the male: female sex ratio for contracting the infection and recovery rate is comparable, recent studies indicate PACS to be more prevalent in females, with increasing age and BMI. Taken together these are hallmark etiological factors and demographics underlying diverse autoimmune pathologies. Third, the lung being the primary affected organ may be the site of chronic auto inflammation itself. There is evidence of auto reactivity and detectable autoantibodies in sputa associated with autoimmune diseases with pulmonary complications (such as rheumatoid arthritis, vasculitis). Finally, there is a growing body of anecdotal evidence highlighting autoimmune diagnoses post-COVID, ranging from Guillain Barre to vasculitis to lupus, in otherwise previously healthy individuals. Our preliminary data suggests 35% of individuals post-COVID have >2 circulating autoantibodies at a high disease-modifying titre, significantly associated with health outcomes. While viruses, in general, have the innate capacity to induce autoimmunity (may not be specific to SARS-CoV2), the magnitude of PACS individuals affected warrants further investigation.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 120 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Investigating the Relationship Between Development of Autoimmunity Due to Severe Acute Respiratory Syndrome (SARS)-Corona Virus-2 (CoV2) Infection and Long-term Health Post Recovery
Actual Study Start Date : June 25, 2021
Estimated Primary Completion Date : March 25, 2024
Estimated Study Completion Date : March 25, 2024

Subjects with Post Acute Sequale SARS-CoV-2 (PSAC)
Participants with PASC
Subjects with COVID but not PASC
Subjects confirmed COVID-19 positive without Post Acute Sequale SARS-CoV-2 (PASC)

Primary Outcome Measures :
  1. Development of auto antibodies (in blood and/or sputum) in PACS and a clinical diagnosis of an autoimmune condition over time . [ Time Frame: Baseline to 18 months ]
    Detection of autoantibodies in PASC and a clinical diagnosis of an autoimmune condition over time .

Biospecimen Retention:   Samples Without DNA
Serum and sputum

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Confirmed COVID diagnosis by PCR/sero-positive based and deemed recovered by public health.

A control age-sex matched population who had symptoms (infection) and tested negative for SARS-CoV2 with a PCR test, will be recruited.

A control age-sex matched population (n=20) with no infection within 4 weeks of recruitment or ever tested positive for COVID and with no known medical conditions and a non-significant smoking history (less than ten years of smoking history).


Inclusion Criteria:

  • 18 years up
  • Positive PCR or antibody test
  • 12 weeks post acute Covid infection with PASC

Exclusion Criteria:

  • Pre-existing Auto- immune disease
  • Chronic/ secondary infections
  • Active Neoplasm
  • Pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT05459506

Layout table for location contacts
Contact: Snehal Somalwar 905-522-1155 ext 35594

Layout table for location information
Canada, Ontario
St. Joseph's Healthcare Hamilton Recruiting
Hamilton, Ontario, Canada, L8N 4A6
Contact: Snehal Somalwar    905-522-1155 ext 35594   
Sponsors and Collaborators
McMaster University
Layout table for investigator information
Principal Investigator: Manali Mukherjee, PhD McMaster University
Layout table for additonal information
Responsible Party: McMaster University Identifier: NCT05459506    
Other Study ID Numbers: COV-IMM001
First Posted: July 15, 2022    Key Record Dates
Last Update Posted: February 14, 2023
Last Verified: February 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by McMaster University:
Post Acute Sequelae
Long Covid
Auto Immune
Additional relevant MeSH terms:
Layout table for MeSH terms
Virus Diseases
Lung Diseases
Respiratory Tract Diseases
Pneumonia, Viral
Respiratory Tract Infections
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections